ABHI (Association of British Healthcare Industries) rejects new UK assessment rules
This article was originally published in Clinica
The Association of British Healthcare Industries (ABHI) has rejected the new methods for assessing medical technology in the UK. While welcoming the broad principles of the new National Institute for Clinical Excellence (NICE) - "faster access to modern treatment" - it argues that its methods are not appropriate to the medical systems industry and that it could hold many drawbacks, including delays in the introduction of new technology, static guidelines for clinical procedures and the threat of rationing.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.